Ivermectin (22,23-dihydroavermectin B1a + 22,23-dihydroavermectin B1b) is a broad-spectrum antiparasitic medication. It is traditionally used against worms, but more recently found to be effective against mites and some lice too. Ivermectin is currently being used to help eliminate river blindness (onchocerciasis) in the Americas and stop transmission of lymphatic filariasis around the world.
Researchers from Sorbonne Université have been reviewing papers exploring different anti-COVID-19 drugs.
When state senators in South Carolina held two hearings in September about covid-19 treatments, they got an earful on the benefits of ivermectin — which many of the lawmakers echoed, sharing experiences of their own loved ones.
In a recent review, the author discusses autophagy as a contributing mechanism of selected drugs that are currently being evaluated to treat COVID‐19.
Scientists from the University Of New Mexico have recently identified a new cationic oligomer that may help inactivate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Researchers plan to provide a comprehensive summary of data from cruise ship outbreaks and explore models of transmission at sea.
In a paper published in the journal Cell, researchers have investigated and criticized clinical care management and drug administration within the pandemic.
A new study describes the nature and extent of the shift in dispensing these medications, as well as its eventual outcome.
A treatment combining two antibodies (casirivimab and imdevimab) is recommended for two specific groups of patients with covid-19 by a WHO Guideline Development Group (GDG) panel of international experts and patients in The BMJ today.
Earlier this month, Dr. Rashid Buttar posted on Twitter that covid-19 "was a planned operation" and shared an article alleging that most people who got the covid vaccine would be dead by 2025.
In a recent study, researchers investigate the possibility of using the thiazolide antiparasitic nitazoxanide for the treatment of COVID-19.
India continues to grapple with the coronavirus disease (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To date, the country has reported over one million new cases for the past 28 days.
Ivermectin, a drug used to treat parasites such as scabies in humans and intestinal helminths in cattle, was screened in 2020 for activity against COVID-19. Laboratory tests suggested a weak effect on SARS-CoV-2 virus in a test tube but did not seem feasible in humans as the doses needed would be large.
New research describes the use of integrative bioinformatics analyses of transcriptomic profiles for COVID-19 therapeutics.
Researchers from the LSTM based Cochrane Infectious Disease Group explored whether community administration of ivermectin influences malaria transmission.
One of the pressing questions scientists are currently trying to answer is whether the current vaccines will remain effective against the emerging SARS-CoV-2 variants of concern. A new piece of research has been published in the journal Biomedicines, which discusses the knowledge we have gained thus far and the questions that researchers should address in future work.
Could a decades-old antidepressant be a secret weapon against covid? A few scientists think so, after two small studies showed that fluvoxamine, typically prescribed for obsessive-compulsive disorder, prevented serious illness in all participants who took the pills soon after developing symptoms.
Millions of children weighing less than 15kg are currently denied access to Ivermectin treatment due to insufficient safety data being available to support a change to the current label indication.
The clinical phenotype of COVID-19, caused by SARS-CoV-2, is remarkable for its wide range of severity among individual patients. Genetic variations are known to mediate part of these differences. To examine these differences, researchers in a new study used human induced pluripotent stem cells (iPSCs) from different genetically diverse individuals. These cells are used to model genetic disease since they contain the donor’s genetic information. Researchers use a panel of iPSCs from over 500 individuals. The researchers preferred undifferentiated iPSCs to reduce the time required to differentiate them, especially since infection is not always reliable.
McMaster University researchers are leading a large international study to test drugs to treat COVID-19 patients.
A team of researchers based in Peru and the U.S. recently examined the role of the anti-parasitic drug ivermectin in treating COVID-19.